Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2.

× No keyword cloud information.

15 in total

Review 1. Leflunomide: a review of its use in active rheumatoid arthritis.

Authors: A Prakash; B Jarvis
Journal: Drugs Date: 1999-12 Impact factor: 9.546

2. Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata.

Authors: Kabir Sardana; Aastha Gupta; Pulin Kumar Gupta
Journal: Clin Rheumatol Date: 2019-07-23 Impact factor: 2.980

Review 3. A review of immunologic diseases of the dog.

Authors: N C Pedersen
Journal: Vet Immunol Immunopathol Date: 1999-08-02 Impact factor: 2.046

Review 4. Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors: F C Breedveld; J M Dayer
Journal: Ann Rheum Dis Date: 2000-11 Impact factor: 19.103

5. The effect of various disease-modifying anti-rheumatic drugs on the suppressive function of CD4⁺CD25⁺ regulatory T cells.

Authors: Ji Seon Oh; Yong-Gil Kim; Seung Geun Lee; Min Wook So; Seung Won Choi; Chang-Keun Lee; Bin Yoo
Journal: Rheumatol Int Date: 2012-03-27 Impact factor: 2.631

6. Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes.

Authors: E Kozer; M E Moretti; G Koren
Journal: Can Fam Physician Date: 2001-04 Impact factor: 3.275

7. Teriflunomide Modulates Vascular Permeability and Microglial Activation after Experimental Traumatic Brain Injury.

Authors: Karthik S Prabhakara; Daniel J Kota; Gregory H Jones; Amit K Srivastava; Charles S Cox; Scott D Olson
Journal: Mol Ther Date: 2018-07-05 Impact factor: 11.454

8. Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report.

Authors: H Ulusoy; A Bilgici; O Kuru; C Celenk
Journal: Rheumatol Int Date: 2004-08-21 Impact factor: 2.631

Review 9. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.

Authors: Nicola Alcorn; Sarah Saunders; Rajan Madhok
Journal: Drug Saf Date: 2009 Impact factor: 5.606

10. Review of teriflunomide and its potential in the treatment of multiple sclerosis.

Authors: Clemens Warnke; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal: Neuropsychiatr Dis Treat Date: 2009-06-10 Impact factor: 2.570